Identification of CLEC-1 Ligand and Uses Thereof
OwnerVanessa Gauttier, Caroline Mary +4inventors
InventorsVanessa Gauttier, Caroline Mary, Nicolas Poirier, Emmanuelle Wilhelm, Géraldine Teppaz, Elise Chiffoleau
Life of this patent
Estimating the term…
Abstract
The invention relates to the use of compounds that reduce the signaling pathway induced by CLEC-1/TRIM21 interaction, in particular compounds that antagonize the interaction, in particular the binding between CLEC-1 and TRIM21, the use of the identified ligand TRIM21 for designing treatment in a patient, in the identification of cells susceptible to interact with cells expressing CLEC-1, and their uses in therapy.
Claims26
1-30. (canceled)
A compound that is an antagonist of the binding between CLEC-1 and TRIM21, in particular an antagonist of the binding between human CLEC-1 and human TRIM21, for use in the treatment of a human subject suffering from a cancer with TRIM21 positive tumor cells.
A method for selecting a compound which modulates, in particular which enhances or reduces, more particularly which inhibits, the interaction between C-type lectin-like receptor-1 (CLEC-1) and tripartite motif-containing protein 21 (TRIM21), in particular a compound that is an antagonist of the binding between CLEC-1 and TRIM21, in particular between human CLEC-1 and human TRIM21, said method comprising:
- a) Providing at least one compound and assessing its(their) capability to interfere with the interaction between CLEC1 and TRIM21, more particularly which competes with or antagonizes binding between CLEC-1 and TRIM21, in particular the interaction is determined between CLEC-1 and at least one domain of TRIM21;
- b) Measuring in presence of the compound the binding between CLEC-1 and TRIM21,
- c) when the compound(s) enhance(s) or decrease(s) the binding between CLEC1 and TRIM21 measured in step b) as compared to a negative control, identifying the compound(s) which modulate(s) the interaction between CLEC-1 and TRIM21, in particular the compound(s) which enhance(s) or reduce(s) the interaction between CLEC-1 and TRIM21.
Dependencies are inferred from the claim text.